Rear Window
Clinuvel board praises "unusual, amazing" CEO Philippe Wolgen
The Clinuvel board reckons CEO Philippe Wolgen is "of a different calibre". We don't disagree.
Joe AstonColumnistThere are companies on the fringes of the ASX 200 that are easily mistaken for asylums. One of them is Clinuvel Pharmaceuticals.
Take this excerpt from the remuneration report within its preliminary annual report filed on Thursday. “In recent weeks, the remuneration committee and board has been surprised, impressed but proud to learn that our CEO has waived and rejected his STI awarded to him for achieving 70 per cent of the KPIs for 2020,” wrote the committee’s chairman, William Blijdorp.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles